May 5, 2026

GAITHERSBURG, Md. and GENEVA, April 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has entered into an agreement with Substipharm Biologics valued at approximately $34.5 million to support drug substance manufacturing for its Japanese Encephalitis (JE) vaccine, licensed internationally under the brand name IMOJEV® at Emergent’s Canton, Massachusetts facility, and for Emergent to serve as the exclusive distributor of the vaccine to the U.S. government, following potential U.S. Food & Drug Administration (FDA) regulatory endeavors.

COLUMBIA, Md., (April 29, 2026) — TEDCO, Maryland’s economic engine for technology companies, announced a recent $500,000 Venture Funds investment in ICaPath located in Baltimore, Md. The Venture Fund is dedicated to growing the next generation of early-stage businesses in Maryland.

“With TEDCO’s support, we will continue to unlock the full power of immunotherapy while improving safety and patient monitoring,” said Brock Lindsey, founder and chairman of the board of ICaPath. “By combining advanced nanoparticle engineering with a clear regulatory strategy, our company is advancing a promising immunotherapy platform with the potential to significantly impact some of the hardest to treat cancers.”

ROCKVILLE, MD, May 04, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that it entered into an expanded royalty purchase agreement with Sagard in exchange for a capped royalty interest on future global net sales of ZYNYZ® (retifanlimab-dlwr). MacroGenics and Sagard entered into the initial ZYNYZ royalty purchase agreement in June 2025.

ZYNYZ is a PD-1 inhibitor originally developed by MacroGenics and licensed to Incyte Corporation pursuant to an exclusive global collaboration and license agreement in October 2017. MacroGenics retains its other economic interests related to ZYNYZ, including future potential development, regulatory and commercial milestones.

WASHINGTON, May 4, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant) is now commercially available across the United States for the prevention of vomiting induced by motion in adults, marking the first new prescription medicine approved for this condition in more than 40 years. An innovative direct-to-consumer order platform is now available through nereus.us.

Motion sickness affects an estimated 65 to 78 million Americans—roughly 25 to 30 percent of adults—during everyday travel by car, plane, or boat. For decades, patients have had no meaningful new treatment options. That changes today with NEREUS™, an oral neurokinin-1 (NK-1) receptor antagonist that offers a modern, targeted approach to a problem that has long lacked innovation.

On April 22, 2026, Georgetown University hosted its annual Research & Innovation Showcase, bringing together faculty, students, investors, entrepreneurs, and regional leaders for a full day focused on translating discovery into real-world impact. Held at the Rafik B. Hariri Building, the event centered on this year’s theme, “Partnerships Power Possibilities,” highlighting how collaboration drives innovation from lab to market.

“The 2026 Georgetown University Research & Innovation Showcase highlighted the need for strategic partners to achieve research translation and innovation development,” said Tatiana Litvin-Vechnyak, Georgetown’s vice president for technology commercialization. “This year’s event brought together more than 400 investors, entrepreneurs, industry stakeholders, faculty, and students, all critical to our ability to achieve this goal. BHI’s collaboration over the years and sponsorship of the showcase has been crucial to this work.”

BioHealth Capital Region Week will return on September 15 through 17, 2026, at US Pharmacopeia in Rockville, Maryland, bringing together leaders from industry, academia, government, and investment for three days focused on the future of one of the nation’s leading biohealth ecosystems. The event will again feature the BioHealth Capital Region Forum, the Crab Trap Competition, and the Investment Conference.

This year’s Forum theme, “Growing the BioHealth Capital Region of Tomorrow,” reflects both the region’s momentum and the need for continued collaboration at a time when many organizations are navigating a more uncertain funding environment. As public funding conditions shift, the region’s long-term strength will depend on its ability to deepen partnerships, support commercialization, attract investment, and build new pathways for growth. The Forum will serve as a place for those conversations to happen.

BELTSVILLE, Md., May 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and Simcere Zaiming Pharmaceutical Co., Ltd., (Simcere) an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096), today announced initiation of the dose optimization portion of the Phase 1 study of SIM0505, focusing on patients with platinum-resistant ovarian cancer. SIM0505 is an investigational antibody drug conjugate (ADC) comprised of an antibody that targets Cadherin-6 (CDH6) and a proprietary topoisomerase 1 inhibitor (TOPOi) payload.

“Initiation of dose optimization highlights the promise of our novel CDH6-directed ADC and our focus on bringing SIM0505 to patients as quickly as...

Maternal health is one of the most urgent challenges in healthcare—and one of the greatest opportunities for innovation. 

Join the National Heart, Lung, and Blood Institute (NHLBI) and March of Dimes for the upcoming “Maternal Health Innovation: From Idea to Impact” five-part virtual event. This series will highlight resources for translational researchers and early-stage companies developing novel technologies for addressing maternal mortality and morbidity. Attendees will learn about current gaps in maternal healthcare and topics relevant to product development such as fundraising, regulatory approvals, reimbursement, non-dilutive funding, and business plan development. 

The kickoff for this series will be held on May 6, 2026 at 12:00 p.m. ET and subsequent sessions will be held every other week.

GAITHERSBURG, Md., April 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a multi-year agreement with SAB Biotherapeutics, Inc. (Nasdaq: SABS, SAB BIO) to support the process development and manufacturing of SAB-142, SAB BIO’s lead program in clinical development for autoimmune type 1 diabetes (T1D). The executed agreement is valued at approximately $50 million, of which $36 million is contingent on future regulatory approval and downstream milestones.

Under the terms of the agreement, Emergent will provide end-to-end development and manufacturing services to SAB BIO that are compliant with current good manufacturing practices. These services will include process development and scale-up, technology and analytical method transfer, manufacturing for SAB-142’s ongoing clinical program and commercial manufacturing services upon regulatory approval.

BHI Board Member Prashant Panchal, MS, MBA, Director, Business Planning & Operations at AstraZeneca, will participate in Biotech, Borders, and Security: Reshoring the Future of U.S. Manufacturing on Wednesday, May 13, from 5:00 to 7:30 PM at Montgomery College’s Bioscience Education Center in Germantown.

Hosted by BioBuzz Networks in partnership with PIC MC at Montgomery College, the event will explore how reshoring, supply chain resilience, national security, and workforce development are shaping the future of U.S. biomanufacturing. Prashant will join the panel “Reshoring & Building Maryland’s Biotech Manufacturing Advantage,” which will examine how Maryland can strengthen its position as a leader in domestic biotech manufacturing.

The program also includes a fireside chat on building a U.S. Strategic API Reserve, followed by networking and tours of the Bioscience Education Center.

FREDERICK, Md., April 30, 2026 /PRNewswire/ -- Theradaptive, Inc., a clinical-stage biotechnology company pioneering targeted protein therapeutics for tissue regeneration, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the Company to initiate the pivotal Phase 3 clinical trial evaluating OsteoAdapt® SP, its next-generation regenerative therapeutic for spinal fusion procedures.

The OASIS trial is evaluating OsteoAdapt SP as an alternative to autologous and allograft bone graft in single-level Transforaminal Lumbar Interbody Fusion (TLIF), Anterior Lumbar Interbody Fusion (ALIF), and Lateral Lumbar Interbody Fusion (LLIF) procedures for the treatment of symptomatic degenerative diseases of the lumbosacral spine. Theradaptive is the only advanced therapeutics company conducting investigational device exemption (IDE) studies with indications across all three of these surgical indications, positioning it to address the majority of spinal fusion needs.

 By Sara Gilgore – Staff Reporter, Washington Business Journal

Apr 27, 2026 - Altimmune Inc. has raked in $225 million in a public offering to fund a critical clinical trial for what leadership hopes will be the company’s first product to market.

The Gaithersburg biopharma said Monday it secured that capital at closing Friday from an offering of 64.25 million shares of common stock, and that it intends to put the roughly $211.2 million in net proceeds toward a phase 3 study of a drug for serious liver diseases. That’s slated to kick off in the second half of 2026 and take about a year to complete.

The therapy candidate, called pemvidutide, is a GLP-1 the company is testing in metabolic dysfunction-associated steatohepatitis, or MASH — a severe type of liver disease that can cause liver failure and death, and is linked to obesity, diabetes and other conditions. Within the past two years, regulators have approved two therapies for MASH, but there’s still demand for more treatments, as MASH is thought to affect up to 12% of U.S. adults and is a leading driver of liver transplants.

(SUBSCRIPTION REQUIRED)

The Johns Hopkins Center for Innovative Diagnostics for Infectious Diseases is joining Innovation Translation at the Johns Hopkins Bloomberg School of Public Health in celebrating its first anniversary with Innovation Week, a series of events highlighting public health innovation, applied research, and real-world translation.

CIDID will be featured in the opening event, “Designing Diagnostics for Real-World Impact,” on Wednesday, May 6, from 3:30 to 5:30 p.m. ET in Sheldon Hall, 615 N. Wolfe St. The panel will include CIDID Director Yukari Manabe and CIDID Innovation Awardee Alex Trick, Co-founder and CEO of Prompt Diagnostics. Dave Hickey, Health Advisory Board member, will moderate the discussion, which will explore the experience of designing public health diagnostic tools that can move from concept to meaningful use.

The event is free to attend, and registration is available at the event link. Innovation Week will continue with additional programming, including the AI + Health Care Idea Tank and Public Health Innovation Stories featuring Bloomberg School faculty.

When BridgeBio Pharma prepared to sell the heart drug Attruby on its own, investors and analysts were skeptical. The San Francisco-area biotechnology firm was competing with two large companies with experienced sales forces, and its chances of success seemed slim.

Optimistic investors believed BridgeBio, at best, could rake in $100 million in sales for the year. But Attruby easily blew past those projections, earning $362 million in 2025 and proving BridgeBio a viable threat to its bigger rivals.

Now, those analyst notes — the skeptical and the optimistic — are framed in the background of a room in BridgeBio’s San Francisco office, where Matt Outten, its chief commercial officer, sometimes takes meetings. “When people come in, they see the good ones, and also the ones where people are like, ‘you could never do it,’” Outten told BioPharma Dive. “The nice thing is, I’m starting to have to replace the early notes with the positive ones.”

The District of Columbia takes second place primarily for its strong economic performance. Like New Hampshire, the federal district scores well in economic viability, highlighted by its high per capita personal income of $111,185. This points to strong earning — and spending — potential among residents.

The district also fares well in digital infrastructure, equipping residents with reliable internet connectivity for their online activity. Where it slightly stumbles, however, is in workforce readiness and quality of life, posting a high unemployment rate of 7.05%. Despite these challenges, its strong overall economic health is able to offload some of these pressures.

Save the date for Bench, Bedside & Breakthrough: Health Tech Innovation from Silicon Valley to BioHealth Capital Region. On Tuesday, May 26, MedStar-Georgetown's AI CoLab brings clinicians, scientists, founders, and investors together for a one-day symposium tracing how a domain-expert insight becomes a regulated, funded, market-ready product.


May 26, 2026 · 9:00 AM – 7:30 PM 


MedStar-Georgetown AI CoLab, Washington, DC